Source link : https://www.newshealth.biz/health-news/duchenne-muscular-dystrophy-gene-therapy/
The FDA’s recent expanded approval of delandistrogene moxeparvovec (Elevidys) widened access to the gene therapy to include ambulatory and non-ambulatory Duchenne muscular dystrophy patients ages 4 and older with a confirmed DMD mutation. In June 2024, the FDA converted its previous accelerated approval to traditional approval for ambulatory Duchenne patients ages 4 and up, and […]
Author : News Health
Publish date : 2024-07-01 18:33:50
Copyright for syndicated content belongs to the linked Source.
Categories